Physician profile
John C Miller
NPI 1932113719
$2,300.31
in general payments reported to CMS, 2019-2025
26 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $125 · 2022: $635 · 2023: $586 · 2024: $433 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.24 | 2019-2025 | |
| Novo Nordisk INC | $487.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $126.90 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $125.42 | 2019-2024 | |
| Otsuka America Pharmaceutical, INC. | $101.54 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $97.52 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $88.21 | 2020-2024 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $87.68 | 2022-2025 | Ensite |
| Convatec INC. | $79.54 | 2020 | |
| Exact Sciences Corporation | $71.51 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $69.66 | 2024-2025 | Veozah |
| Tempus Ai, INC | $68.69 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.64 | 2023-2024 | Jardiance |
| Amgen INC. | $46.43 | 2019-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.02 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $41.05 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $28.10 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $26.57 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $21.96 | 2020 | |
| Romark Laboratories, Lc | $19.61 | 2019 | |
| Phathom Pharmaceuticals, INC. | $17.05 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.72 | 2022 | |
| Dynavax Technologies Corporation | $13.58 | 2022 | |
| Amarin Pharma, INC. | $12.50 | 2019 | |
| Mylan Specialty L.P. | $12.12 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.